Swiss National Bank Has $2.94 Million Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Swiss National Bank trimmed its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,694 shares of the life sciences company’s stock after selling 1,400 shares during the quarter. Swiss National Bank’s holdings in Integra LifeSciences were worth $2,941,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter worth about $180,000. Centiva Capital LP bought a new position in Integra LifeSciences in the 3rd quarter valued at about $192,000. Dynamic Technology Lab Private Ltd acquired a new position in Integra LifeSciences during the 3rd quarter valued at about $198,000. Finally, Romano Brothers AND Company bought a new stake in Integra LifeSciences during the 4th quarter worth approximately $204,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of IART opened at $21.82 on Thursday. The stock has a 50 day moving average of $23.85 and a 200 day moving average of $22.12. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -242.42, a PEG ratio of 0.73 and a beta of 1.23. Integra LifeSciences Holdings Co. has a 12 month low of $16.81 and a 12 month high of $35.49. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the previous year, the business posted $0.89 EPS. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.